Is 0.25mg Semaglutide Effective — and What Is It Actually Doing?

What the STEP 1 trial actually tells us about the starting dose

The STEP 1 trial enrolled 1,961 adults with obesity or overweight and at least one weight-related condition. Over 68 weeks, those on semaglutide 2.4mg lost an average of around 15% of their body weight compared with roughly 2.4% on placebo. That headline figure is the number most people encounter, and it belongs to the maintenance dose, not the 0.25mg opener.

The trial's titration schedule mirrors the licensed one: participants began at 0.25mg and progressed through four-weekly steps. Researchers specifically designed that stepped approach to reduce early gastrointestinal side effects rather than to deliver early weight loss. In other words, the 0.25mg phase is protective scaffolding for the dose increases ahead. Expecting meaningful fat loss at this stage misreads what the medicine is doing.

That said, some people notice a modest reduction in appetite even at 0.25mg. That is real (semaglutide acts on GLP-1 receptors in the brain and gut from the first dose) but the signal is subtle, and it should not be mistaken for the treatment having reached full effect. The NHS medicines page for semaglutide sets this out clearly, noting that the dose is increased gradually to reduce side effects.

Patience here is not passive. It is exactly what the evidence asks of you.

How the 0.25mg dose fits into the full semaglutide schedule

Wegovy's licensed titration runs from 0.25mg through 0.5mg, 1mg and 1.7mg, arriving at the 2.4mg maintenance dose after roughly 16 weeks. A prescriber can slow this if side effects make a step difficult to tolerate. Since April 2026, the MHRA has also approved a 7.2mg maintenance option, delivered via a dedicated single-dose pen, for adults with a BMI of 30 or above, though that higher dose is only appropriate for certain patients and confirmed at clinical assessment.

Thinking about how weight loss accumulates across the schedule helps set realistic expectations. The 0.25mg phase tends to produce little measurable weight change. By 0.5mg and beyond, appetite suppression becomes more pronounced for most people, and many patients start to notice meaningful changes at that point. By the time maintenance is reached, the trial data shows consistent, substantial results for those who continue. If you want to understand how the picture changes dose by dose, the full Wegovy dose guide explains each step and what to expect from it.

One practical note: your pen arrives in a plain, unbranded box via DPD with tracked delivery, so you will know exactly when it lands. The pen itself is a pre-filled weekly injection (single-use, pre-set to your current dose) stored in the fridge until the morning you use it.

Side effects at 0.25mg, what is normal and what warrants a call

Most of the side effects people experience on Wegovy appear early, when semaglutide is new to the system. Nausea is the most frequently reported, along with loose stools, constipation, burping, fatigue and headache. At 0.25mg these tend to be milder than at higher doses, which is precisely the logic behind starting there.

For most people, GI symptoms settle within the first week or two. Eating smaller meals, avoiding high-fat foods and staying well hydrated all help. Symptoms that are severe or persistent (especially severe stomach pain that radiates toward the back) are a reason to seek prompt medical advice, because acute pancreatitis is a known, though infrequent, side effect of GLP-1 medicines. The MHRA highlighted this in a Drug Safety Update published in January 2026. Any suspected side effect can be reported directly at yellowcard.mhra.gov.uk.

Temporary nausea at the start is not a signal that the treatment is failing. It is evidence the medicine is doing what it is supposed to do before your prescriber decides it is time to move you up.

Who qualifies for Wegovy, and how to begin

Under its UK licence, semaglutide (Wegovy) is available to adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, obstructive sleep apnoea or dyslipidaemia. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. NICE's appraisal of semaglutide (TA875) sets out the NHS criteria, which are narrower: a specialist weight management service, a maximum of two years of treatment, and a BMI of at least 35 for most people. The private route through a regulated pharmacy like nume does not require a referral or a waiting list, provided you meet the licensed eligibility criteria on clinical assessment.

Pregnancy, breastfeeding, and planning a pregnancy are contraindications. Under-18s are not covered by the licence. History of medullary thyroid carcinoma or certain gastrointestinal conditions needs discussion with a prescriber before starting. For anyone considering treatment, the question of which dose is actually effective is worth reading alongside this page, and if you are curious about whether the 1mg dose delivers meaningful results on its own, that question is covered in detail too. It is also worth noting that semaglutide is licensed strictly as a weight management medicine, so if you have come across information about how semaglutide dosage is sometimes discussed in bodybuilding contexts, the approach and intent differ significantly from the clinical protocol followed here.

If you want to understand the broader landscape of options, including how Wegovy compares with other approaches, the weight-loss treatment overview covers the full picture. When you are ready to find out whether Wegovy is clinically right for you, checking your eligibility with our prescribers is the straightforward next step.